Latest News - DexCom
Top Corporates Hub
DexCom
Citi reiterates these 2 medtech stocks as its top picks in the sector
08.10.2026 07:40
Investing.com-- Citi reiterated its top picks in the medtech sector, highlighting Abbott Laboratories and Dexcom as standout opportunities while pointing to diverging fortunes across the industry.
Dexcom Schedules Third Quarter 2026 Earnings Release and Conference Call for October 29, 2026 at 4:30 p.m. Eastern Time
07.10.2026 12:30
SAN DIEGO, October 07, 2026--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its third quarter 2026 financial results after market close on Thursday, October 29, 2026. Management will hold a conference call to review the company's third quarter 2026 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and wil
Barclays Initiates Coverage On DexCom with Overweight Rating, Announces Price Target of $115
07.10.2026 08:37
Barclays analyst Christopher Pasquale initiates coverage on DexCom (NASDAQ:DXCM) with a Overweight rating and announces Price Target of $115.
DexCom (NASDAQ:DXCM): Strong Growth Paired With a High-Quality Technical Setup
02.10.2026 11:00
DexCom shows strong growth, top-tier profitability, and a constructive chart setup, making it a standout pick for growth screens with defined technical levels.
Tandem Diabetes Care (TNDM) Is Up 7.2% After International Launch Of Mobi Insulin Pump System
01.10.2026 01:22
Tandem Diabetes Care has recently launched its Tandem Mobi automated insulin delivery system in 12 countries across Europe and Israel, using Dexcom G7 continuous glucose monitoring and Control-IQ+ technology to automatically adjust insulin every 5 minutes. The international rollout of this small, iPhone-controlled pump with flexible wear options and a 200-unit cartridge broadens Tandem’s technology ecosystem for people living with diabetes outside the United States. We’ll now explore how...
Tandem Diabetes Care (TNDM) Is Up 7.2% After International Launch Of Mobi Insulin Pump System
01.10.2026 01:22
Tandem Diabetes Care has recently launched its Tandem Mobi automated insulin delivery system in 12 countries across Europe and Israel, using Dexcom G7 continuous glucose monitoring and Control-IQ+ technology to automatically adjust insulin every 5 minutes. The international rollout of this small, iPhone-controlled pump with flexible wear options and a 200-unit cartridge broadens Tandem’s technology ecosystem for people living with diabetes outside the United States. We’ll now explore how...
Tandem Diabetes Care (TNDM) Is Up 7.2% After International Launch Of Mobi Insulin Pump System
01.10.2026 01:22
Tandem Diabetes Care has recently launched its Tandem Mobi automated insulin delivery system in 12 countries across Europe and Israel, using Dexcom G7 continuous glucose monitoring and Control-IQ+ technology to automatically adjust insulin every 5 minutes. The international rollout of this small, iPhone-controlled pump with flexible wear options and a 200-unit cartridge broadens Tandem’s technology ecosystem for people living with diabetes outside the United States. We’ll now explore how...
DexCom (DXCM) Stock Looks Cheap Based On Future Cash Flow
25.09.2026 00:20
DexCom shares have delivered a mixed ride in recent years, and that uneven path raises a simple question for anyone looking at the chart today. Is the current US$87.47 price adequately supported by the cash the business is expected to generate over time? Over the past 5 years the stock has declined 36.0%, which puts the focus squarely on whether the cash flow story still lines up with the share price. The recent move to expand Jereme Sylvain’s remit to Chief Operating Officer as well as...
Is DexCom (DXCM) Cheap After Its Leadership Reshuffle Or Already Fairly Priced?
24.09.2026 04:29
DexCom (DXCM) just reshuffled its leadership team, with longtime finance chief Jereme Sylvain stepping into a combined EVP and Chief Operating Officer role that now includes responsibility for global operations and quality. Recent boardroom moves at DexCom have arrived at a time when the 90-day share price return of 27.79% and year-to-date gain of 31.85% point to building momentum. However, the 1-year total shareholder return of 29.97% contrasts with a weaker 3-year record and a deeper 5-year...
Global Wearable Biosensors Market Trends, Strategies and Forecast to 2036 Featuring Abbott Labs, Dexcom, Medtronic, Roche, Apple, Samsung Electronics Co., Garmin and Other Key Players
21.09.2026 09:04
Dublin, Sept. 21, 2026 (GLOBE NEWSWIRE) -- "Wearable Biosensors Market - Global Forecast to 2036" has been added to ResearchAndMarkets.com's offering.According to the research report, the global wearable biosensors market is projected to reach USD 105.5 billion by 2036 from USD 35.5 billion in 2026, growing at a CAGR of 12.5% during the forecast period (2026-2036). The growth of this market is primarily driven by the escalating demand for continuous health monitoring, the rising prevalence of ch
DexCom (NASDAQ:DXCM): An Affordable Growth Play With Strong Momentum and Fair Valuation
27.08.2026 11:21
Discover why DexCom (DXCM) fits the Affordable Growth screen, balancing strong earnings growth with reasonable valuation and solid financial health.
Here's How Much You'd Have If You Invested $1000 in DexCom a Decade Ago
13.08.2026 12:30
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
DexCom (NASDAQ:DXCM) Stands Out as an Affordable Growth Stock
04.08.2026 11:10
DexCom earns a 7/10 fundamental rating, blending strong growth, reasonable valuation, and solid profitability as an affordable growth pick.
DexCom (DXCM) Q2 2026 Earnings Call Transcript
04.08.2026 00:15
Revenue hit $1.31 billion with strong international growth and margin expansion.
DexCom: Still A Cautious Buy Following Earnings
03.08.2026 07:16
Dexcom (DXCM) Q2 earnings beat: G7 adoption, global expansion lift margins and FY26 guidance.
DexCom (DXCM) Stock Sees Fair Value Lift After Analyst Target Increases
02.08.2026 06:10
DexCom’s fair value estimate has shifted from US$85.24 to US$91.64, marking a moderate uplift in the price target range currently referenced for the stock. This move lines up with recent analyst commentary, where many firms are reaffirming or raising targets, while a smaller group trims expectations on valuation concerns and growth assumptions. As you read on, you will see how these price target adjustments fit into the broader DexCom narrative and what to watch to stay aligned with the...
Why DexCom (DXCM) Is Up 16.6% After Raising 2026 Outlook And Expanding Type 2 Access
01.08.2026 14:10
In late July 2026, DexCom reported second-quarter results showing higher sales and earnings than a year earlier and raised its full-year 2026 revenue outlook to US$5.18 billion–US$5.25 billion, implying around 11–13% growth. Beyond the headline numbers, DexCom highlighted progress in expanding access for type 2 diabetes patients not using insulin and advancing next-generation sensors, underlining its push into broader metabolic health monitoring. We’ll now look at how DexCom’s raised 2026...
DXCM Q2 Deep Dive: Expanded Access and Product Updates Drive Growth
01.08.2026 04:19
Medical device company DexCom (NASDAQ:DXCM) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 13.1% year on year to $1.31 billion. The company expects the full year’s revenue to be around $5.22 billion, close to analysts’ estimates. Its non-GAAP profit of $0.70 per share was 15.1% above analysts’ consensus estimates.
DexCom, Inc. 2026 Q2 - Results - Earnings Call Presentation
31.07.2026 05:32
2026-07-31. The following slide deck was published by DexCom, Inc.
DexCom Inc (DXCM) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth and Raised Guidance ...
31.07.2026 05:04
DexCom Inc (DXCM) delivered 13% revenue growth and raised full-year guidance, driven by strong international performance and improved margins.